PV Bulletin
PvBulletin
Home /Regulators/FDA Public Notification: Tawon Liar Contains Hidden Drug Ingredients
RegulatorsFDAUnited States

FDA Public Notification: Tawon Liar Contains Hidden Drug Ingredients

FDA advises consumers not to purchase or use Tawon Liar due to undisclosed active ingredients including tapentadol, dexamethasone, and meloxicam.

PV Impact Brief

Urgency: HighConfidence: high
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementLabeling
Action needed

Review product inventory for Tawon Liar; report any adverse events to FDA MedWatch; consider adding product to signal monitoring list; ensure labeling compliance checks for similar products.

Owner

Regulatory Intelligence Lead

Review cadence

as needed

Regulatory action details

Action type
Public Notification
Publication date
2026-05-29
Safety issue
Contains hidden drug ingredients which may cause serious side effects or interactions.

Affected products

  • Tawon Liar

PV internal implications

Monitor for adverse events from unapproved drug ingredients.

View regulator source

Evidence and confidence

Confidence: highSource updated: May 29, 2026

Full briefing

What changed

FDA updated its public notification regarding Tawon Liar on May 29, 2026, adding detection of tapentadol, dexamethasone, and meloxicam. Previous notifications in 2023 and 2022 reported meloxicam, ketorolac, and dexamethasone.

Why it matters

The product contains undeclared active pharmaceutical ingredients, including a controlled opioid, an NSAID, and a corticosteroid, which can cause serious adverse reactions, drug interactions, and have abuse potential.

Practical implication

Review product inventory for Tawon Liar; report any adverse events to FDA MedWatch; consider adding product to signal monitoring list; ensure labeling compliance checks for similar products.

#Safety Signals#Hidden Ingredients#FDA#Public Notification#other#firecrawl-agent#regulatory-extraction

Related updates for your role

RegulatorsMHRAUnited Kingdom

MHRA Class 2 Recall: ChloraPrep 2% applicators (potential sterility breach)

Regulatory action
Class 2 Medicines Recall
ChloraPrep 2% 1mL applicator · Becton Dickinson UK Ltd
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Identify and quarantine all impacted batches of ChloraPrep 2% 1mL and Frepp 2% 1.5mL applicators; return to Becton Dickinson UK Ltd.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsHealth CanadaCanada

Omnipod Insulin Management System Recall in Canada

Regulatory action
Health product recall
Omnipod Insulin Management System · Insulet Corporation
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Identify affected lots and implement recall procedures as per Health Canada guidelines.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsMedicines and Healthcare products Regulatory Agency (MHRA)United Kingdom

MHRA Largest Seizure of Unlicensed Weight Loss Medicines

Regulatory action
Enforcement Action / Public Safety Alert
Unlicensed weight loss medicines · Illicit manufacturing operation (unnamed)
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsEuropean Medicines Agency (EMA)European Union

EMA ETF recommends updating COVID-19 vaccines to target XFG variant for 2026/2027 campaign

Regulatory action
Regulatory Recommendation / Public Health Communication
COVID-19 vaccines · Marketing authorisation holders (various)
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: MonitorConfidence: high
Read impact brief →
FDA Public Notification: Tawon Liar Contains Hidden Drug Ingredients | PV Bulletin